| Formulations | Generic and branded pharmaceutical formulations across multiple therapeutic areas including oncology, gynecology, cardiology, dermatology, and animal health. | Strong R&D, FDA approvals, diversified product portfolio, established distribution in India and US, and exclusive product licenses. | B2B and B2C; includes hospitals, clinics, pharmacies, healthcare providers, and animal health sectors. | Specialty therapies, oncology, ophthalmology, and dermatology formulations with higher value realization. | 5539 | 83 | Revenue primarily from product sales to wholesalers, hospitals, pharmacies and government agencies in domestic and international markets. | Direct product sales with competitive pricing; includes branded generics and specialty product tiers. | New product launches, approvals in regulated markets, expansion in specialty therapies, and growing international demand. | Azithral, Tellzy, Wikoryl, Gestofit, Rosave, Althrocin |
| Active Pharmaceutical Ingredients (API) | Manufacturing and sale of active pharmaceutical ingredients used in-house and for external pharma manufacturers globally. | In-house API production, regulatory compliance, and strategic alliances with global pharma companies. | Pharmaceutical manufacturers globally, including in regulated markets. | Specialty APIs with complex synthesis processes. | 1133 | 17 | Sales of APIs to pharmaceutical companies and for captive use. | Contract manufacturing and bulk sales to clients, priced competitively in a global API market. | Global demand for APIs, partnerships with pharma companies, and expansion into new geographical markets. | Azithromycin, Leflunomide, Lacosamide |
